Eukarys
Private Company
Funding information not available
Overview
Eukarys is a Paris-based biotech developing a disruptive platform technology to enhance biomanufacturing productivity. Its flagship C3P3® system is an mRNA-based, artificial RNA polymerase that boosts protein yield by 5-7x in standard mammalian cell lines like CHO and HEK-293, without requiring changes to existing manufacturing processes. The company targets the production of antibodies, recombinant proteins, viral vectors, and other biologics, partnering with pharmaceutical and biotech firms to integrate its technology and reduce development timelines and costs. As a private, pre-revenue platform company, Eukarys is focused on commercial validation and strategic partnerships.
Technology Platform
C3P3®: A patented artificial RNA polymerase technology that performs mRNA synthesis and post-transcriptional modifications inside mammalian cells to boost protein production yields by 5-7x. It is universal across cell lines and biologic types, integrates into existing processes, and preserves product quality.
Opportunities
Risk Factors
Competitive Landscape
Eukarys competes with companies focused on cell line engineering (e.g., Selexis, Catalent GPEx), process intensification, and alternative expression systems. Its differentiation lies in its mRNA-based, intracellular enzyme approach that claims universal applicability and seamless integration without changing core manufacturing equipment.